PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/690,115
Filing Date	October 21, 2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	COLEMAN
Attorney Docket Number	PRD 2033 NP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear Class	Subclass
BC		USPN 3,886,160		Tweit, Robert C.	05-27-1975	544	316
BC		USPN 3,714,179		Tweit, Robert C.	01-30-1973	548	315.7
BC		USPN 5,030,644		Baldwin et al.	07-09-1991	514	393
BC		USPN 5,217,986		Pomponi, S.A. et al.	06-08-1993	514	400
BC		USPN 5,352,707		Pompni, S.A. et al.	10-04-1994	514	651
BC		USPN 5,869,479		Kreutner, W.; Hey, J.A.	02-09-1999	514	217.05

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	KindCode[5]	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T[6]
BC	✓	WO	99/42458		James Black Foundation Limited	08-26-1999		
BC	✓	EP	0978512	A1	Societe Civile Bioprojet	02-09-2000		
** BC	✓	JP	02306237	A2	Kato et al.	12-19-1990		
BC	✓	WO	02/076925	A2	Eli Lilly and Company	10-03-2002		
BC	✓	WO	03/050099	A1	Ortho-McNeil Pharmaceutical, Inc.	06-19-2003		
BC	✓	WO	02/024695	A2	Ortho-McNeil Pharmaceutical,Inc.	03-28-2002		
BC	✓	WO	02/012214	A2	Ortho-McNeil Pharmaceutical, Inc.	02-14-2002		
BC	✓	WO	02/012190	A2	Ortho-McNeil Pharmaceutical, Inc.	02-14-2002		
BC	✓	WO	03/064411	A1	Novo Nordisk	08-07-2003		
BC	✓	WO	03/031432	A1	Novo Nordisk	04-17-2003		
BC	✓	WO	03/024929	A1	Novo Nordisk	03-27-2003		
BC	✓	WO	03/004480	A2	Novo Nordisk	01-16-2003		
BC	✓	WO	03/024928	A2	Novo Nordisk	03/27/2003		

Examiner Signature	Brenda Coleman	Date Considered	May 30, 2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

** structures only

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/690,115
Filing Date	October 21, 2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	COLEMAN
Attorney Docket Number	PRD 2033 NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
BC		ALBENGRES, E. et al. Systemic Antifungal Agents. Drug Safety (Feb. 1998) 18(2):83-97	
BC		ALI, S.M. et al. Design, Synthesis, and Structure-Activity Relationships of Acetylene-Based Histamine H3 Receptor Antagonists. J. Med. Chem. (1999) 42(5):903-909	
BC		ARRANG, J.-M. et al. Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor. Nature (April 1983) 302:832-837	
BC		ASH, A.S.F.; SCHILD, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac. Chemother. (1966) 27:427-439	
BC		BACK, D.J.; TJIA, J.F. Inhibition of Tolbutamide Metabolism by Substituted Imidazole Drugs In Vivo: Evidence for a Structure-Activity Relationship. Br. J. Pharmacol. (1985) 85:121-126	
BC		BARNES, J.C. et al. The Selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release In Vivo. Soc. Neurosci. Abstr. (1993) 19:1813	
BC		Bioworld Today, March 2, 1999, page 3	
BC		BLACK, J.W. et al. Definition and Antagonism of Histamine H2-Receptors. Nature (April 1972) 236:385-390	
BC		DING, Y.-S. et al. Synthesis of High Specific Activity (+)- and (-)-6-[18F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction. J. Med. Chem. (1991) 34(2):767-771	
BC		GANELLIN, C.R. et al. Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists. Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) (1998) 331:395-404	
BC		GARBARG, M. et al. S-[2-(4-Imidazolyl)ethyl]isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist. J. Pharmacol. Exp. Ther. (1992) 263(1):304-310	
BC		Gliatech Inc. Press Release Nov. 5, 1998	
BC		GONZALEZ, F. GARCIA, et al. Synthesis of 3-aryl(alkyl)-4-(D-arabino-tetrahydroxybutyl)imidazoline-2-thiones, Carbohydrate Research, 22(2), 436-40 (English) 1968	
BC		ICHINOSE, M.; BARNES, P.J. Histamine H3-Receptors Modulate Nonadrenergic Noncholinergic Neural Bronchoconstriction in Guinea-Pig In Vivo. Eur. J. Pharmacol. (1989) 174(1):49-55	
BC		IMAMURA, M. et al. Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release. J. Pharmacol. Exp. Ther. (1994) 271(3):1259-1266	
BC		JONES, R.G. Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboylates fromGlycine and Substituted Glycine Esters. J. Am. Chem. Soc. (1949) 71:644-647	
BC		JORDAAN, A., ARNDT, R.R., The Synthesis of 1-Methyl-5-(α-indolyl)imidazole and 1-Methyl-2-ethylthiol-5-(α-indolyl)imidazole. Journal of Heterocyclic Chemistry 5(5), 723-5 (English) 1968	
BC		KAPETANOVIC, I.M.; KUPFERBERG, H.J. Nafimidone, an Imidazole Anticonvulsant, and Its Metabolite as Potent Inhibitors of Microsomal Metabolism of Phenytoin and Carbamazepine. Drug Metab. Dispos. (1984) 12(5):560-564	
BC		KORTE, A. et al. Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by N alpha-Methylhistamine. Biochem. Biophys. Res. Commun. (May 1990) 168(3):979-986	
BC		KRAUSE, M. et al. Medicinal Chemistry of Histamine H3 Receptor Agonists; In The Histamine H3 Receptor - A Target for New Drugs Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 175-198	
BC		LAVRIJSEN, K. et al. Induction Potential of Antifungals Containing an Imidazole or Triazole Moiety. Biochem. Pharmacol. (1988) 35(11):1867-1878	
BC		LEURS, R. et al. The Medicinal Chemistry and Therapeutic Potentials of Ligands of the Histamine H3 Receptor. Prog. Drug Res. (1995) 45:107-165	
BC		LEURS, R. et al; "Therapeutic potential of histamine H3 recepto agonists and antagonitsts" Trends n Pharmacological sciences, Elsevier Trends Journal, Cambridge, BG, vol. 19, no. 5, 1 May 1998; Pages 177-184, XP004121095	
BC		LIN, J.-S. et al. Involvement of Histaminergic Neurons in Arousal Mechanisms Demonstrated with H3-Receptor Ligands in the Cat. Brain Res. (1990) 523:325-330	
BC		LINNEY, I.D. et al. Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists. J. Med. Chem. (2000) 43(12):2362-2370	
BC		LOVENBERG, T.W. et al. Cloning and Functional Expression of the Human Histamine H3 Receptor. Mol. Pharmacol. (1999) 55:1101-1107	
BC		LOVENBERG, T.W. et al. Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. (2000) 293(3):771-778	
BC		MACHIDORI, H. et al. Zucker Obese Rats: Defect in Brain Histamine Control of Feeding. Brain Res. (1992) 590:180-188	
BC		MCLEOD, R.L. et al. Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist. Soc. Neurosci. Abstr. (1998) 22:2010	
BC		MEIER, G. et al. Piperidino-Hydrocarbon Compounds as Novel Non-Imidazole Histamine H3-Receptor Antagonists. Bioorg. Med. Chem. (2002) 10:2535-2542	
BC		MONTI, J.M. et al. Effects of Selective Activation or Blockade of the Histamine H3 Receptor on Sleep and Wakefulness. Eur. J. Pharmacol. (1991) 205(3):283-287	
BC		MORISSET, S. et al. High Constitutive Activity of Native H3 Receptors Regulates Histamine Neurons in Brain. Nature (Dec. 2000) 408:860-864	
BC		ODA, T. et al. Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes. J. Biol. Chem. (2000) 275(47):36781-36786	
BC		PANULA, P. et al. Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease. Soc. Neurosci. Abstr. (1995) 21:1977	

BC	✓	PHELPS, M.E. Positron Emission Tomography Provides Molecular Imaging of Biological Processes. Proc. Natl. Acad. Sci. (2000) 97(16):9226-9233	
BC	✓	PHILLIPS, J.G.; ALI, S.M. Medicinal Chemistry of Histamine H3 Receptor Antagonists; In The Histamine H3 Receptor - A Target for New Drugs Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 197-222	
BC	✓	PHILLIPS, J.G. et al. Chapter 4, Recent Advances in Histamine H_3 Receptor Agents. Ann. Reports in Med. Chem., 31, 1998, pages 31-40	
BC	✓	ROULEAU, A. et al. Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, a Histamine H3 Receptor Agonist Prodrug. J. Pharmacol. Exp. Ther. (1997) 281(3):1085-1094	
BC	✓	SABBATINI, RENATO,M.E., The Cyclotron and PET. In Brain & Mind an electronic magazine about Neuroscience [online]. March, 1997. Retrived from the internet, <http:www.epub.org.br/cm/n01/pet/petcyclo.htm.	
BC	✓	SCHLICKER, E.; MARR, I. The Moderate Affinity of Clozapine at H3 Receptors Is Not Shared by Its Two Major Metabolites and by Structurally Related and Unrelated Atypical Neuroleptics. Naunyn-Schmiedeberg's Arch. Pharmacol. (1996) 353:290-294	
BC	✓	SHEETS, J.J.; MASON, J.I. Ketoconazole: a Potent Inhibitor of Cytochrome P-450-Dependent Drug Metabolism in Rat Liver. Drug Metab. Dispos. (1984) 12(5):603-606	
BC	✓	STARK, H. et al. Developments of Histamine H3-Receptor Antagonists. Drugs Future (1996) 21(5):507-520	
BC	✓	TOZER, M.J., et al.: "From Histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3 receptor antagonists"; Bioorganic & Medicinal CHemistry Letters, OXFORD, GB, vol. 9, no. 13, 5 July 1999, Pages:1825-1830, XP004168846	
BC	✓	TOZER, M.J.; KALINDJIAN, S.B. Histamine H3 Receptor Antagonists. Exp. Opin. Ther. Patents (2000) 10(7):1045-1055	
BC	✓	WALCZYNSKI, K. et al. Non-Imidazole Histamine H3 Ligands, Part 2: New 2-Substituted Benzothiazoles as Histamine H3 Antagonists. Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) (1999) 332:389-398	
BC	✓	WALCZYNSKI, K. et al. Non-Imidazole Histamine H3 Ligands. Part I. Synthesis of 2-(1-Piperazinyl)- and 2-(Hexahydro-1H-1,4-diazepin-1-yl)benzothiazole Derivatives as H3-Antagonists with H1 Blocking Activities. Farmaco (1999) 54:684-694	
BC	✓	WEST, R.E. et al. Identification of Two H3-Histamine Receptor Subtypes. Mol. Pharmacol. (1990) 38(5):610-613	
BC	✓	WEST, R.E., Jr. et al. The Profiles of Human and Primate [3H]N alpha-methylhistamine Binding Differ from That of Rodents. Eur. J. Pharmacol. (1999) 377:233-239	
BC	✓	YOKOYAMA, H. et al. Effect of Thioperamide, a Histamine H3 Receptor Antagonist, on Electrically Induced Convulsions in Mice. Eur. J. Pharmacol. (1993) 234:129-133	
BC	✓	ANJANEYULU, B. et al. Synthesis of 14C-Labelled 1-Methanesulphonyl-3-(1-methyl-5-nitro-1*H*-imidazol-2-yl)-2-imidazolidinone, (Go 10213). J. Labelled Compd. Radiopharm. (1983) 20(8):951-961	
BC	✓	IEMURA, R. et al. Synthesis of Benzimidazole Derivatives as Potential H1-Antihistaminic Agents. J. Heterocycl. Chem. (1987) 24:31-37	
BC	✓	IWATA, R. et al. Synthesis of 3-[1*H*-Imidazol-4-yl]propyl 4-[18F]fluorobenzyl Ether ([18F]Fluoroproxyfan): A Potential Radioligand for Imaging Histamine H3 Receptors. J. Labelled Compd. Radiopharm. (2000) 43:873-882	
BC	✓	JAROSINSKI, M.A.; ANDERSON, W.K. Preparation of Noncondensed 2-Substituted 1-Methylimidazoles via Ipso Substitution Reaction on 2-Sulfinyl or 2-Sulfonyl Derivatives of 4,5-Disubstituted 1-Methylimidazoles. J. Org. Chem. (1991) 56(12):4058-4062	
BC	✓	OHTA, S. et al. Synthesis and Application of Imidazole Derivatives. Introduction of Carbogenic Substituents into the 5-Position of 1-Methyl-1*H*-imidazole. Chem. Pharm. Bull. (1992) 40(10):2681-2685	
BC	✓	PHILLIPS, B.T. et al. Preparation of 5-Substituted 2-Mercapto-1-methylimidazoles. Direct Metalation of 2-Mercapto-1-methylimidazole. Synthesis (1990) :781-783	
BC	✓	SCHNETTLER, R.A. et al. 4-Aroyl-1,3-dihydro-2*H*-imidazol-2-ones, a New Class of Cardiotonic Agents. J. Med. Chem. (1982) 25:1477-1481	
BC	✓	SHAPIRO, G.; MARZI, M. Synthesis of 2,5-Dilithio-1-methylimidazole. Tetrahedron Lett. (1993) 34(21):3401-3404	
BC	✓	ERDELYI, M.; GOGOLL, A. Rapid Homogeneous-Phase Sonogashira Coupling Reactions Using Controlled Microwave Heating. J. Org. Chem. (2001) 66(12):4165-4169	
BC	✓	APODACA, R. et al. A New Class of Diamine-based Histamine H3 Receptor Antagonists: 4-(Aminoalkoxy)benzylamines. J. Med. Chem. (2003) 46(18):3938-3944	
BC	✓	STARK, H. Recent Advances in Histamine H3/H4 Receptor Ligands. Expert Opin. Ther. Patents (2003) 13(6):851-865	
BC	✓	Phenylalkynes to Treat Histamine-Mediated Conditions. Expert Opin. Ther. Patents (2003) 13(11):1759-1762	

Examiner Signature	Brenda Coleman	Date Considered	May 30, 2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/690,115
Filing Date	October 21, 2003
First Named Inventor	Ricahrd L. Apodaca et al.
Group Art Unit	1624
Examiner Name	COLEMAN
Attorney Docket Number	PRD-2033

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	KindCode[5]	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T[6]
BC		EP	0 186 817	A1	Nissan Chemical Industries Ltd.	07-09-1986		
BC		WO	03/055866	A1	Bayer Corporation	07-10-2003		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
BC		BARN, David R. et al., "Synthesis of an Array of Amides by Aluminium Chloride Assisted Cleavage of Resin-Bound Esters", Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, Netherlands, Vol. 37, No. 19, pp. 3213-3216, April 1996	

Examiner Signature	Brenda Coleman	Date Considered	May 30 2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SUBMISSION UNDER MPEP 609 D

Page 2 of 2

Application Number	10/690,115
Filing Date	October 21, 2003
First Named Inventor	Richard L. Apodaca et al.
Group Art Unit	1624
Examiner Name	COLEMAN
Attorney Docket Number	PRD-2033

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.[1]	Name of Patentee or Applicant of Cited Document	U.S. Patent Document Number	Kind Code[2] (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.[1]	Name of Patentee or Applicant of Cited Document	Foreign Patent Document Office[3]	Number[4]	KindCode[5]	Pages, Columns, Lines, where relevant passages or relevant figures appear	T[6]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
BC		PCT International Search Report, dated March 31, 2004, for PCT Int'l. Appln. No. PCT/US03/33343	

Examiner Signature	Brenda Coleman	Date Considered	May 30, 2006

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/690,115
Filing Date	10/21/03
First Named Inventor	R. L. APODACA
Group Art Unit	1624
Examiner Name	COLEMAN
Attorney Docket Number	PRD-2033

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
BC		Applicants' letter dated August 26, 2006 citing 3D-Pharmaceutials Ex #43	

Examiner Signature	Brenda Coleman	Date Considered	May 30, 2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.